After Talks With FDA on Iluvien, Alimera Sees Need for New Trials Eliminated

Drug Industry Daily
A A
Alimera Sciences’ negotiations with the FDA on Iluvien have put the diabetic macular edema drug on a glide path to potential approval — a startling about-face following three complete response letters (CRL) for the drug’s application.

To View This Article:

Login

Subscribe To Drug Industry Daily